-computer-image.png)
Gastroesophageal Reflux Disease
Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in which acid-containing contents from the stomach seep back up into the oesophagus, causing damage to the lower esophageal sphincter (LES), a muscle that connects the esophagus to the stomach. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Trusted Source, GERD affects about 20 % of people in the United States.
DelveInsight presents a new addition to its newsletter edition that focuses on the Gastroesophageal Reflux Disease market. The newsletter offers a complete picture of the Gastroesophageal Reflux Disease market landscape, ongoing clinical trials, pipeline therapies that are expected to transform the Gastroesophageal Reflux Disease market in the coming decade. Gain rich insights into GERD epidemiological insights, current treatment therapies, details of the latest news and happenings, mergers and collaborations, critical pharmaceuticals involved, licensing deals along with events and top-level conferences taking place in the Gastroesophageal Reflux Disease field.
Interested in knowing more about what upcoming years hold for the Gastroesophageal Reflux Disease market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Digestive Disorder market.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Market Dynamics
- Collaborations and deals in the domain
